// App-Quantinova.ai

3177 : Cost Effectiveness of Rivaroxaban Versus Warfarin for the Prevention of Recurrent Venous Thromboembolism.

Researchers

Presenter

  • Margaret V. Ragni

Principal Investigators

  • Kenneth J. Smith

Medical Centers

  • Division of Hematology/Oncology, University of Pittsburgh Medical Center, Pittsburgh, PA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Cardiovascular (CVS)

  • Blood/haematological Diseases

  • Pulmonary/Respiratory Diseases

Disease

  • Venous thrombosis

Biomarkers

  • N/A

Drug/Treatment

  • rivaroxaban

  • Warfarin

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved